TRIGLIDE Drug Patent Profile

Which patents cover Triglide, and when can generic versions of Triglide launch?

Triglide is a drug marketed by Skyepharma Ag and is included in one NDA.

The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Triglide

A generic version of TRIGLIDE was approved as fenofibrate by RHODES PHARMS on May 13^th, 2005.

Summary for TRIGLIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	138
Clinical Trials:	3
Patent Applications:	4,095
Drug Prices:	Drug price information for TRIGLIDE
DailyMed Link:	TRIGLIDE at DailyMed

See drug prices for TRIGLIDE

See drug sales revenues for TRIGLIDE

Recent Clinical Trials for TRIGLIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lindsay Ferguson, MD	Phase 1
Medical University of South Carolina	Phase 4
National Heart, Lung, and Blood Institute (NHLBI)	N/A

See all TRIGLIDE clinical trials

US Patents and Regulatory Information for TRIGLIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Skyepharma Ag	TRIGLIDE	fenofibrate	TABLET;ORAL	021350-001	May 7, 2005		DISCN	No	No
Skyepharma Ag	TRIGLIDE	fenofibrate	TABLET;ORAL	021350-002	May 7, 2005	BX	RX	Yes	No

Expired US Patents for TRIGLIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Skyepharma Ag	TRIGLIDE	fenofibrate	TABLET;ORAL	021350-001	May 7, 2005
Skyepharma Ag	TRIGLIDE	fenofibrate	TABLET;ORAL	021350-002	May 7, 2005

International Patents for TRIGLIDE

See the table below for patents covering TRIGLIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2440355	COMBINAISONS STATINE ET FIBRATE PRESENTANT DES EFFETS SECONDAIRES ALIMENTAIRES INDESIRABLES A JEUN-NOURRI REDUITS (FIBRATE-STATIN COMBINATIONS WITH REDUCED FED-FASTED EFFECTS)
Australia	2001259099
Germany	60127457

TRIGLIDE Market Analysis and Financial Projection Experimental

Fibrate Drugs Market: Dynamics and Financial Trajectory for Triglide (Fenofibrate)

Market Overview

The global fibrate drugs market, which includes medications like Triglide (fenofibrate), is poised for significant growth over the next decade. Here are the key dynamics and financial projections for this segment.

Market Size and Growth

The global fibrate drugs market was valued at USD 3.25 billion in 2023 and is expected to grow to USD 5.41 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 5.22% from 2024 to 2033[1][3][4].

Regional Dominance

North America currently holds the largest share of the fibrate drugs market, driven by a well-established healthcare infrastructure, a high incidence of cardiovascular diseases, and extensive use of fibrate treatments for lipid disorders. The U.S. market alone was valued at USD 890 million in 2023 and is projected to reach USD 1.51 billion by 2033, growing at a CAGR of 5.42% during this period[1][4].

Europe's Growing Demand

Europe is expected to show the fastest growth in the fibrate drugs market during the forecast period. The increasing incidence of cardiovascular diseases and metabolic disorders, along with supportive regulatory policies and rising healthcare spending, are driving the demand for effective lipid-lowering treatments like fenofibrate[1].

Drug Type Insights

Fenofibrate Segment

The fenofibrate segment, which includes brand names like Triglide, is anticipated to witness significant growth. Fenofibrate is highly effective in lowering triglyceride levels and improving lipid profiles, making it a preferred choice for treating hypercholesterolemia and severe hypertriglyceridemia. The segment's growth is attributed to its high efficacy and the increasing number of patients suffering from these conditions[2][3].

Product Type Insights

Branded vs. Generic

The branded segment dominated the fibrate drugs market in 2023, but generic versions are gaining traction. Generic fenofibrate, such as the one launched by Lupin in 2021, offers the same benefits as branded versions but at a lower cost, increasing market competition and driving demand[1][3][4].

Distribution Channels

Fibrate drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. The hospital and retail pharmacy segments are significant due to the high volume of prescriptions filled through these channels[1].

Factors Driving Growth

Increasing Prevalence of Cardiovascular Diseases

The global increase in cardiovascular disorders is a major driver for the fibrate drugs market. High triglyceride levels and low HDL cholesterol are associated with a higher risk of heart attacks and strokes, making fibrates like fenofibrate essential in managing these conditions[1][3][4].

Impact of Diabetes

The rising prevalence of diabetes worldwide also contributes to the market growth. High blood sugar levels can increase triglycerides and lower HDL cholesterol, increasing the risk of heart disease and thus the demand for fibrate drugs[3].

Regulatory Approvals and Product Launches

Recent product launches and regulatory approvals, such as the approval of Aurobindo Pharma's fenofibrate capsules by the FDA, are expected to fuel market growth. These approvals increase the availability of effective fibrate drugs, driving demand and market expansion[4].

Restraining Factors

Availability of Alternate Treatment Options

The availability of alternative treatment options for lipid disorders can limit the demand for fibrate drugs. However, the specific benefits of fibrates, such as their ability to reduce triglyceride levels and boost HDL cholesterol, maintain their relevance in the market[3].

Safety Concerns and Regulatory Framework

Safety concerns, particularly with older fibrates like clofibrate, and a stringent regulatory framework can hinder market growth. Any resurgence in the use of older fibrates would require strong scientific evidence and regulatory backing[1].

Real-World Efficacy of Fenofibrate

Studies have shown the efficacy of fenofibrate in real-world settings. For instance, a study published in PLOS ONE found that fenofibrate significantly reduced triglyceride levels by a median of 60% over a follow-up period of 4 months. This efficacy supports the continued use and growth of fenofibrate in the market[5].

Financial Trajectory for Triglide (Fenofibrate)

Given the overall market trends, the financial trajectory for Triglide (fenofibrate) is positive. Here are some key financial insights:

• Market Size: The segment including fenofibrate is expected to grow significantly, contributing to the overall market size of USD 5.41 billion by 2033[1].
• Revenue Growth: With a CAGR of 5.22% from 2024 to 2033, the revenue from fenofibrate sales is anticipated to increase substantially[1].
• Regional Contribution: The U.S. market, where Triglide is widely prescribed, is expected to grow from USD 890 million in 2023 to USD 1.51 billion by 2033[1].

Key Takeaways

• The global fibrate drugs market is expected to grow to USD 5.41 billion by 2033.
• North America dominates the market, with the U.S. being a significant contributor.
• The fenofibrate segment is anticipated to witness significant growth due to its efficacy in lowering triglyceride levels.
• Regulatory approvals and product launches are key drivers of market growth.
• Safety concerns and alternative treatment options are potential restraining factors.

FAQs

What is the primary use of fenofibrate in medical treatment?

Fenofibrate is primarily used to treat severe hypertriglyceridemia and high cholesterol, helping to lower triglyceride levels and increase HDL (good) cholesterol[2].

How does the cost of fenofibrate vary?

The cost of fenofibrate can vary based on factors such as treatment plan, insurance coverage, and the pharmacy used[2].

What are the regional market dynamics for fibrate drugs?

North America currently holds the largest market share, but Europe is expected to show the fastest growth due to increasing incidence of cardiovascular diseases and supportive regulatory policies[1][4].

What are the key drivers of the fibrate drugs market?

The increasing prevalence of cardiovascular diseases, rising diabetes rates, and regulatory approvals for new products are key drivers of the market[1][3][4].

How effective is fenofibrate in real-world settings?

Fenofibrate has been shown to significantly reduce triglyceride levels by a median of 60% over a follow-up period of 4 months in real-world studies[5].

Sources

1. Precedence Research: "Fibrate Drugs Market Size to Worth USD 5.41 Billion by 2033"
2. Medical News Today: "Fenofibrate cost 2024: Coupons and more"
3. Polaris Market Research: "Fibrate Drugs Market Size, Demand, Trends, Report, 2024-2032"
4. Mordor Intelligence: "Fibrate Drugs Market - Size, Share & Statistics"
5. PLOS ONE: "Real-world results and factors associated with triglyceride reduction"